Alerta

一种多功能纳米复合材料的制备方法及其应用

Resumen de: CN120478306A

本发明适用于生物医学技术领域，提供了一种多功能纳米复合材料的制备方法及其应用。该材料生物相容性良好，可作为安全制剂用于肿瘤治疗；制备简便且绿色无污染；扩展了槲皮素在抗肿瘤免疫治疗中的应用；具有优异的荧光/计算机断层扫描双模式成像性能，可用于确定肿瘤边界，实现精准治疗引导；具有优良的光热及光热增强的催化性能，具备微创高效、毒副作用小且可控等优势，能通过激活免疫有效治疗原发、转移或复发性头颈部鳞状细胞癌；通过诱导肿瘤细胞释放2’3’‑cGAMP并防止其降解，高效激活cGAS‑STING信号通路，最终增强抗肿瘤免疫效果。

一种mRNA脂质纳米粒及其制备方法和应用

Resumen de: CN120478287A

本发明涉及纳米生物技术领域，提出了一种mRNA脂质纳米粒及其制备方法和应用。该mRNA脂质纳米粒，通过透明质酸酶（HAase）修饰以降解肿瘤细胞外基质中的透明质酸，改善肿瘤微环境，降低肿瘤组织的屏障作用，从而增强mRNA‑LNP的渗透性。此外，该体系在肿瘤微酸环境下可发生粒径翻转，提高肿瘤深层细胞的递送效率。实验结果表明，该递送体系可有效提高mRNA在肿瘤组织中的渗透能力和抗肿瘤疗效，为肿瘤基因治疗提供了一种新的策略。

呕吐毒素致断奶仔猪肠道铁死亡的抑制剂及制备方法

Resumen de: CN120478304A

本发明涉及畜牧技术领域，尤其涉及一种呕吐毒素致断奶仔猪肠道铁死亡的抑制剂及制备方法，本发明整合铁螯合剂(去铁胺，DFO)、GPX4激活剂(硒甲硫氨酸，SeMet)及抗炎成分(姜黄素、黄芪多糖、双氢青蒿素)，覆盖铁蓄积、GPX4失活、脂质过氧化等铁死亡三大核心通路；同时，采用pH敏感型壳聚糖‑海藻酸钠纳米颗粒对以上成分进行包被，使其能够过胃，避免受到胃酸的破坏，确保药物在肠道的碱性环境中精准释放，从而提高药物的利用率；并且，硒甲硫氨酸、姜黄素、黄芪多糖、双氢青蒿素均为天然来源，可以避免化学药物残留风险，可作为饲料添加剂应用于断奶仔猪当中。

具格兰氏阴性菌抗菌活性的螯合型复合胶束及其应用

Resumen de: WO2024153108A1

The present invention discloses a chelating complex micelle presenting antimicrobial activity against gram-negative bacteria. The chelating complex micelle comprises metal ions, polymers having a chelating segment, and an antimicrobial agent having at least one Lewis base functional group, wherein the antimicrobial agent presenting antimicrobial activity against multi-drug-resistant gram-negative bacteria (MDR-GNB), such as carbapenem-resistant A. baumannii, P.aeruginosa, or Enterobacteriaceae.

一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用

Resumen de: CN120484249A

本发明属于生物医药技术领域，公开了一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用。本发明的所述含氟修饰聚肌氨酸化脂质具有如式(I)或式(II)所示结构通式。通过不同含氟基团化学改性聚肌氨酸化脂质得到的含氟修饰聚肌氨酸化脂质可以替代PEG化脂质制备脂质纳米颗粒(LNP)，用于负载核酸等药物，达到提升药物递送性能的目的。

用于成纤维细胞生长因子受体3介导的至星形胶质细胞的递送的组合物及方法

Resumen de: AU2023379457A1

The present invention provides, in part, protein-drug conjugates comprising an anti-fibroblast growth factor receptor 3 (FGFR3) (e.g., human FGFR3) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, polypeptides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain). Methods for treating various diseases or disorders, such as neurological diseases, with the conjugates are provided.

基于冷萃酶解高温换能技术的骨筋粘膜多靶点复合制剂的制备方法

Resumen de: CN120478581A

本发明公开了基于冷萃酶解高温换能技术的骨筋粘膜多靶点复合制剂的制备方法，涉及医药技术领域。本发明包括以下步骤：步骤一：原料预处理：选用新鲜、无污染的鳕鱼皮和鹿筋作为主要原料，将鳕鱼皮洗净，去除表面的杂质和脂肪，切成边长约0.5‑1cm的小块，鹿筋用30‑40℃温水浸泡12‑15小时进行泡发。本发明通过独特的4‑15℃低温阶段、15‑37℃阶梯升温阶段和脉冲热处理，有效避免了传统热提取对胶原蛋白等热敏性成分的破坏，保留了原料的天然活性，在低温阶段，温和的酶解条件能使原料中的热敏性物质得以完整保留，脉冲热处理则使胶原肽构象转换率提高，显著提升了其生物利用度和活性，更利于人体吸收和利用。

一种DACe@ET纳米药物的制备方法及其应用

Resumen de: CN120478400A

本发明提供了一种DACe@ET纳米药物的制备方法及其应用，制备方法，包括以下步骤：合成金纳米颗粒、金/二氧化铈核核壳结构纳米颗粒、修饰氨基聚乙二醇马来酰亚胺和星形胶质细胞归巢肽DAG；将星形胶质细胞归巢肽DAG和ET‑18‑OCH3加入金/二氧化铈核核壳结构纳米颗粒的溶液中，离心得到DACe@ET纳米药物；DACe@ET纳米药物在脑淀粉样血管病的治疗中的应用，能够调节氧化还原平衡和降低脑内铁沉积；本发明的DACe@ET纳米药物通过提高抗氧化能力，并改善细胞摄取能力，从而提高药物的生物利用度；可有效减少CAA模型小鼠脑内铁的异常积累，恢复脑内氧化还原平衡，表明其具有优异的脑铁稳态调控能力。

一种巨噬细胞-聚合物脂质纳米粒复合递药系统及其制备方法与其在抗隐球菌感染中的应用

Resumen de: CN120478378A

本发明公开了一种巨噬细胞‑聚合物脂质纳米粒复合递药系统及其制备方法与其在抗隐球菌感染中的应用。所述递药系统以α‑亚麻酸(ALA)、高分子量壳寡糖(HCOS)、两性霉素B(AmB)为原料构建纳米粒AmB‑PLHNs，藉由巨噬细胞的吞噬作用将纳米粒负载于巨噬细胞内，构建AmB‑PLHNs@M1。AmB是临床治疗Cn感染的常用药物，但存在肾脏毒副作用以及无法转运进入中枢的问题。AmB‑PLHNs@M1由M1型巨噬细胞的透血脑屏障特性，携带AmB‑PLHNs转运入脑，增加药物入脑效率。结合巨噬细胞对隐球菌的吞噬，结合巨噬细胞的炎症免疫调节功能和载药纳米粒的抑菌作用，用于Cn中枢感染治疗，降低AmB的毒副作用。

一种大孔牛血清白蛋白纳米颗粒及其制备方法和用途

Resumen de: CN120478305A

本发明涉及一种大孔牛血清白蛋白纳米颗粒及其制备方法和用途，其中所述大孔牛血清白蛋白纳米颗粒为表面分布有大孔的纳米颗粒，所述纳米颗粒的尺寸范围为300~645nm，所述大孔为孔径范围为50~100nm的贯穿孔；所述纳米颗粒为对称N面体或球形纳米颗粒，其中N≥12。其比表面积高达20‑60m²/g，显著提升了药物负载能力（5‑25% w/w）与包封效率（50‑90%），较传统表面无孔的纳米颗粒吸附效率大大提升。与表面无孔的BSA纳米颗粒相比，大孔的存在提高了RhB的吸收效率，在药物递送方面具有广泛应用。

表达布鲁氏菌多抗原的混合疫苗及其制备方法和应用

Resumen de: CN120478610A

本发明属于生物医药技术领域，具体涉及一种表达布鲁氏菌多抗原的混合疫苗及其制备方法和应用，所述混合疫苗由脂质纳米颗粒对活性mRNA包封后获得；所述活性mRNA的核苷酸序列如SEQ ID NO.1~SEQ ID NO.8所示中的至少一种。本发明通过利用LNP独立包封编码布鲁氏菌8种关键抗原的mRNA制备所述混合疫苗。本发明所述的混合疫苗，不仅避免了抗原竞争问题，能够高效的被递送至免疫系统，且每种抗原都能引发均衡的免疫反应。

多叔胺多尾链可电离阳离子脂质、包含其的组合物及用途

Resumen de: CN120483890A

本公开属于医药领域，更具体地，涉及递送脂质技术领域，公开了多叔胺多尾链可电离阳离子脂质、包含其的组合物及用途。本公开提供的多叔胺多尾链可电离阳离子脂，其包括如式(I)所示的结构，可用于核酸靶向递送，能够显著增强mRNA疫苗或药物的防脱靶效应。#imgabs0#

一种水溶性自组装的壳聚糖纳米复合物及其制备方法与应用

Resumen de: CN120478651A

本发明公开了一种水溶性自组装的壳聚糖纳米复合物及其制备方法，所述纳米复合物由季铵盐化壳聚糖（O‑HTCC）与5β‑胆烷酸通过共价偶联形成两亲性聚合物NCH复合物，该纳米颗粒的粒径110±8.48 nm，包裹Alda‑1可有效提高Alda‑1的溶解度，包封率36.1%，显著降低DCD供肾移植后IRI损伤，提高线粒体ALDH2活性，使大鼠移植后3天血清肌酐下降至最低水平。本技术适用于离体器官机械灌注液改良，具有临床转化潜力。

用于治疗剂的靶向递送的自组装脂质纳米颗粒

Resumen de: MX2025005244A

The present invention provides delivery system compositions comprising self- assembling lipid nanoparticles for targeted delivery of therapeutic or diagnostic agents to target cells. The particles are non-covalently attached to a lipidated antibody or antibody fragment which comprises an antibody or antibody fragment attached, via a peptide linker, to a lipidated peptide portion, wherein the antibody or antibody fragment is at the distal end from the nanoparticle.

核酸の送達のための硫黄含有化合物及びその組成物

Resumen de: WO2024035783A2

Lipid nanoparticle compositions (LNPs), methods for preparing the LNPs, methods of using the same, including, but not limited to, for treatment of certain diseases and disorders, including, but not limited to liver disorders, kits for the delivery of nucleic acids to various types of cells, including T-cells and hepatocytes, in vivo, ex vivo and in vitro.

MATERIAL AND METHOD OF NUCLEIC ACID DELIVERY CROSSING THE BLOOD‑BRAIN BARRIER AND OTHER BLOOD-TISSUE BARRIERS

Resumen de: WO2025171161A1

Described herein are methods directed to delivering therapeutic agents across the blood-brain barrier (BBB) or other tissue barriers in subjects requiring treatment or care. The method involves obtaining a small molecule comprising a Janus Base with Amino Acid (JBAA) and mixing it in a solution with a therapeutic agent and processing the mixture with sonication to form a nanoparticle (NP) encapsulating the therapeutic agent. The NP is then administered to the subject, facilitating the crossing of the BBB or other tissue barriers to deliver the therapeutic agent directly to target cells. This approach enhances the delivery efficiency of therapeutic agents to specific sites within the body, potentially improving treatment outcomes for conditions requiring targeted delivery across biological barriers.

IONIZABLE CATIONIC COMPOUND

Resumen de: AU2024218499A1

Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.

LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME

Resumen de: WO2025171300A1

Described are compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).

METHODS FOR PRODUCING DERMATOLOGICAL GEL COMPOSITIONS

Resumen de: WO2025171327A1

The disclosure provides a method for preparing a gel formulation comprising (a) sterilizing a first portion, wherein the first portion comprises a gelling agent, and (b) filtering a second portion to remove submicron contaminants, wherein the second portion comprises an aqueous carrier, one or more buffers, an antioxidant, an antimicrobial, a humectant, and a penetration enhancer, and following step (a) and step (b), contacting the first portion with the second portion to produce the gel formulation.

BIODEGRADABLE MAGNESIUM OR MAGNESIUM OXIDE-NANOMETAL CATALYST COMPOSITE PARTICLES FOR REACTIVE OXYGEN SPECIES CONTROL AND USES THEREOF

Resumen de: WO2025170419A1

The present invention relates to a nano-metal composite particle comprising magnesium oxide and manganese oxide, a use of the composite particle as a nanozyme utilizing the ability to scavenge reactive oxygen species, and a manufacturing method therefor.

MESOPOROUS CERIA NANOPARTICLES FOR PREVENTION, TREATMENT, OR ALLEVIATION OF OPHTHALMIC DISEASES

Resumen de: WO2025170320A1

Disclosed herein are mesoporous ceria nanoparticles for the prevention, treatment, or alleviation of ophthalmic diseases. In one aspect, having mesoporous structure with high surface area and pore size and mimicking the catalytic properties of catalase and superoxide dismutase (SOD), the mesoporous ceria nanoparticles of the present invention have excellent ability to scavenge reactive oxygen species, exhibit anti-inflammatory effects, demonstrate biocompatibility without causing acute side effects or ocular toxicity in the retina, and are recognized to provide protective effects against cellular damage and protect damaged retinal pigment epithelial (RPE) cells and photoreceptors under high oxidative stress. Therefore, the nanoparticles can be utilized for the prevention, treatment, or alleviation of macular degeneration and various oxidative stress-mediated ophthalmic diseases.

RECEPTOR- AND MAGNETIC FIELD-TARGETED DRUG CARRIER SYSTEM FOR LIVER CANCER

Resumen de: WO2025170561A1

The invention relates to a drug carrier system, which is an acyaloglycoprotein receptor and magnetically targeted, arabinogalactan-functionalised and doxorubicin-loaded magnetic nanoparticle.

OPTOGENETIC ANTI-INFLAMMATORY COMPOSITION CONTAINING NANOPARTICLES INCLUDING AGENT FOR INHIBITING FORMATION OF NLRP3 INFLAMMASOME AS ACTIVE INGREDIENT

Resumen de: WO2025170309A1

The present invention relates to an optogenetic anti-inflammatory composition containing, as an active ingredient, nanoparticles including an agent for inhibiting the formation of the nod-like receptor protein 3 (NLRP3) inflammasome, wherein the nanoparticles contain: a vector including a polynucleotide encoding a truncated version of cryptochrome-interacting basic-helix-loop-helix 1 (CIBN)-NLRP3 fusion protein; and a vector including a polynucleotide encoding the cryptochrome 2 (CRY2) protein or a variant thereof. The optogenetic anti-inflammatory composition has excellent anti-inflammatory activity due to non-invasive light stimulation and can thus be highly effectively used in related fields.

ECTOSOME COMPRISING CORONA-VIRUS SPIKE PROTEIN AND USE THEREOF

Resumen de: WO2025170343A1

The present invention provides: an ectosome comprising a corona-virus spike protein, wherein the ectosome exhibits improved drug delivery efficiency to lung cancer cells without side effects, and thus exhibits excellent anticancer efficacy; and a use thereof.

STEM CELL-DERIVED NANO ANTICANCER DRUG DELIVERY SYSTEM HAVING IMPROVED TARGETING ABILITY BY USING DEXAMETHASONE

Nº publicación: WO2025170342A1 14/08/2025

Solicitante:

ECTOSOME INC [KR]
GACHON UNIV OF INDUSTRY ACADEMIC COOPERATION FOUNDATION [KR]
\uC8FC\uC2DD\uD68C\uC0AC \uC5D1\uD1A0\uC880,
\uAC00\uCC9C\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8

Resumen de: WO2025170342A1

The present invention provides stem cell-derived membrane vesicle-liposome fusion nanoparticles and a use thereof, the nanoparticles exhibiting tumor site targeting ability and anticancer efficacy superior to those of a conventional drug delivery system having targeting ability.